nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.03.2024

The incidence of major bleeding in adult patients with urogenital and gynecological cancer being treated with direct oral anticoagulants (DOACs): a systematic review

verfasst von: L. Al-Tourah, S. Mithoowani, W Lim, Rick Ikesaka

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Direct oral anticoagulants (DOACs) are the mainstay of treatment for venous thromboembolism (VTE) and non-valvular atrial fibrillation (AF), with or without an underlying cancer. Patients with cancer have a 2-3-fold increase in risk for bleeding complications compared to non-cancer patients taking anticoagulant therapy, however the incidence of bleeding for urogenital and gynecological cancers on DOACs are uncertain.

Aims

To assess the bleeding risk associated with the use of DOACs in patients with urogenital and/or gynecological cancers.

Method

We conducted a systematic review of randomized controlled trials (RCTs) and prospective cohort studies to address the safety of DOACs for VTE and AF when used in patients with urogenital and/or gynecological malignancy. The primary outcomes assessed were major and clinically relevant non-major (CRNMB) bleeding, with minor bleeding considered as a secondary outcome. MEDLINE, EMBASE and COCHRANE Central Registry of Controlled Trials were searched up to and including Oct 28, 2022. The study protocol was registered in PROSPERO (CRD42022370981). Studies were independently assessed for inclusion and data extracted in duplicate.

Result

Seven studies met our inclusion criteria (Fig. 1): 2 RCTs and 5 prospective cohort studies. A total of 676 patients treated with DOACs were included, 628 (92.8%) had VTE and 48 (7.1%) had AF. In patients with VTE treated with DOACs, the pooled major bleeding rate was 2.1%, 95% confidence intervals (CI) 0.9–3.3% (Fig. 2). Pooled estimates could not be determined for AF patients given small event and patient numbers.

Conclusion

Major bleeding rates in urogenital and/or gynecological cancer patients treated with DOACs are similar to that of the general cancer population.

Nur mit Berechtigung zugänglich

Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464. https://doi.org/10.1001/archinte.166.4.458CrossRefPubMed

Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809–815. https://doi.org/10.1001/archinte.160.6.809CrossRefPubMed

Sud R, Khorana AA (2009) Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res 123(Suppl 4):S18–S21. https://doi.org/10.1016/S0049-3848(09)70137-9CrossRefPubMed

Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125(6):490–493. https://doi.org/10.1016/j.thromres.2009.12.023Epub 2010 Jan 25. PMID: 20097409; PMCID: PMC2878879CrossRefPubMedPubMedCentral

Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153. https://doi.org/10.1056/NEJMoa025313CrossRefPubMed

Mulder FI, Bosch FTM, Young AM et al (2020) Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 136(12):1433–1441. https://doi.org/10.1182/blood.2020005819CrossRefPubMed

Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G (2021) Update on guidelines for the management of Cancer-Associated thrombosis. Oncol 26:e24–e40. https://doi.org/10.1002/onco.13596CrossRef

Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J, International Initiative on Thrombosis and Cancer (ITAC) advisory panel (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347. https://doi.org/10.1016/S1470-2045(22)00160-7PMID: 35772465; PMCID: PMC9236567CrossRefPubMedPubMedCentral

Rungjirajittranon T, Owattanapanich W, Chinthammitr Y, Ruchutrakool T, Suwanawiboon B (2022) Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis. Thromb J 20(1):41. https://doi.org/10.1186/s12959-022-00399-7CrossRefPubMedPubMedCentral

10.

Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of Cancer-Associated venous thromboembolism. N Engl J Med 378(7):615–624. https://doi.org/10.1056/NEJMoa1711948CrossRefPubMed

11.

Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor xa inhibitor with low Molecular Weight Heparin in patients with Cancer with venous thromboembolism: results of a Randomized Trial (SELECT-D). J Clin Oncol 36(20):2017–2023. https://doi.org/10.1200/JCO.2018.78.8034CrossRefPubMed

12.

Agnelli G, Becattini C, Bauersachs R et al (2018) Apixaban versus Dalteparin for the treatment of Acute venous thromboembolism in patients with Cancer: the Caravaggio Study. Thromb Haemost 118(9):1668–1678. https://doi.org/10.1055/s-0038-1668523CrossRefPubMed

13.

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411–421. https://doi.org/10.1111/jth.14662CrossRefPubMed

14.

Søgaard M, Nielsen PB, Skjøth F, Kjaeldgaard JN, Larsen TB (2019) Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: a nationwide cohort study. Cancer Med 8(3):1044–1053. https://doi.org/10.1002/cam4.1997Epub 2019 Feb 14. PMID: 30767432; PMCID: PMC6434207CrossRefPubMedPubMedCentral

15.

De Crem N, Peerlinck K, Vanassche T et al (2015) Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res 136(4):749–753. https://doi.org/10.1016/j.thromres.2015.07.030CrossRefPubMed

16.

Ferreira M, Barsam S, Patel JP et al (2016) Heavy menstrual bleeding on rivaroxaban. Br J Haematol 173(2):314–315. https://doi.org/10.1111/bjh.13583CrossRefPubMed

17.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med. ;21(11):1539-58. https://doi.org/10.1002/sim.1186. PMID: 12111919

18.

Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH (2012) Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 49(5):1–15CrossRef

19.

Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.xCrossRefPubMed

20.

Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119–2126. https://doi.org/10.1111/jth.13140CrossRefPubMed

21.

Maraveyas A, Beyer-Westendorf J, Lee AY et al (2021) Cancer-Associated ThrOmboSIs - Patient-reported OutcoMes with RivarOxaban (COSIMO) - baseline characteristics and clinical outcomes. Res Pract Thromb Haemost 5(8):e12604 Published 2021 Nov 30. https://doi.org/10.1002/rth2.12604CrossRefPubMedPubMedCentral

22.

Mulder FI, van Es N, Kraaijpoel N et al (2020) Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study [published correction appears in Thromb Res. 2020;191:156–159]. Thromb Res 185:13–19. https://doi.org/10.1016/j.thromres.2019.11.007CrossRefPubMed

23.

Prins MH, Lensing AW, Brighton TA et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37–e46. https://doi.org/10.1016/S2352-3026(14)70018-3CrossRefPubMed

24.

Renni MJP, Araujo MLC, Jr, Trugilho I, Bergmann A, de Morais E, Coura CP (2017) Rivaroxaban used in the treatment patients with gynecologic Cancer and venous thromboembolism: the experience of Instituto Nacional De Câncer-Rio De Janeiro, Brazil. Int J Gynecol Cancer 27(5):1042–1045. https://doi.org/10.1097/IGC.0000000000000972CrossRefPubMed

25.

Soff GA, Mones J, Wilkins C et al (2019) Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Res Pract Thromb Haemost 3(3):349–356 Published 2019 May 24. https://doi.org/10.1002/rth2.12215CrossRefPubMedPubMedCentral

26.

Russo V, Rago A, Papa AA et al (2018) Use of Non-vitamin K antagonist oral anticoagulants in Atrial Fibrillation patients with malignancy: clinical practice experience in a single Institution and Literature Review. Semin Thromb Hemost 44(4):370–376. https://doi.org/10.1055/s-0037-1607436CrossRefPubMed

27.

Vedovati MC, Giustozzi M, Verdecchia P et al (2018) Patients with cancer and atrial fibrillation treated with DOACs: a prospective cohort study. Int J Cardiol 269:152–157. https://doi.org/10.1016/j.ijcard.2018.07.138CrossRefPubMed

28.

Frere C, Farge D, Schrag D, Prata PH, Connors JM (2022) Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 15(1):69. https://doi.org/10.1186/s13045-022-01289-1. Published 2022 May 21CrossRefPubMedPubMedCentral

29.

Odajima S, Seki T, Kato S, Tomita K, Shoburu Y, Suzuki E, Takenaka M, Saito M, Takano H, Yamada K, Okamoto A (2022) Efficacy of edoxaban for the treatment of gynecological cancer-associated venous thromboembolism: analysis of Japanese real-world data. J Gynecol Oncol 33(5):e62 Epub 2022 Jun 7. PMID: 35712973; PMCID: PMC9428303CrossRefPubMedPubMedCentral

Titel: The incidence of major bleeding in adult patients with urogenital and gynecological cancer being treated with direct oral anticoagulants (DOACs): a systematic review
verfasst von: L. Al-Tourah
S. Mithoowani
W Lim
Rick Ikesaka
Publikationsdatum: 01.03.2024
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2024
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-024-02956-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aims

Method

Result

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

COVID-19 vaccination affects short-term anti-coagulation levels in warfarin treatment

Management of DOAC-related bleeding in cancer patients: a single center-case series

One-year morbidity and mortality in patients treated with standard-dose and low-dose apixaban after acute large vessel occlusion stroke

Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa

Persistent hypofibrinolysis in severe COVID-19 associated with elevated fibrinolysis inhibitors activity